profit from every $100 of sales.
$0$100
ENDRA Life Sciences
$4.77-0.03% today
-12.5% in 1 year
1-year low $3.261-year high $6.70
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What ENDRA Life Sciences sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$7.03 million of profit last year.
SalesProfit
ENDRA Life Sciences vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| ENDRA Life Sciences | No profit yet | ||
 Illumina | 37.9× · Expensive | ||
 Labcorp Holdings | 34.5× · Expensive | ||
 Quest Diagnostics | 28.8× · Fair price | ||
 Guardant Health | No profit yet |
AI analysis
An AI analyst reads ENDRA Life Sciences's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -13 | -11 | -11 | -6 | |
| -13 | -10 | -11 | -6 | |
| -13 | -10 | -12 | -7 | |
| -7,980.00 | -2,766.85 | -56.94 | -8.93 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 9 | 7 | 4 | 4 |
| Cash | 5 | 3 | 3 | 1 |
| Total debt | 1 | 0 | 1 | 0 |
| Total liabilities | 2 | 1 | 2 | 2 |
| 7 | 6 | 3 | 2 | |
| 0 | 0 | 0 | 1 | |
| -134.1% | -137.3% | -271.7% | -165.4% | |
| -182.9% | -177.8% | -449.5% | -310.9% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -13 | -10 | -7 | -5 | |
| 0 | 0 | 0 | 3 | |
| -13 | -10 | -7 | -8 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 1 | 1 | 1 | 0 |
Valuation
- –
- –
- –
- 1.7×
- –
- –
- –
- -72.7%
- -98.2%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -178.3%
- -210.9%
- -496.9%
- -182.4%
- -185.7%
- –
Growth
- –
- –
- +29.9%
- –
- −21.2%
Financial health
- 0.1×
- 0.22
- 12.8%
- –
- 1.29
- 1.29
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 21%of 889
Bottom 1%of 987
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 18, 2026 | -1.09 | -1.23 | +11.4% |
| Mar 31, 2026 | -3.26 | -1.23 | −165.0% |
| Nov 14, 2025 | -1.75 | -1.95 | +10.3% |
| Aug 14, 2025 | -1.71 | -2.27 | +24.7% |
| May 15, 2025 | -2.59 | -3.91 | +33.8% |
| Mar 31, 2025 | -9.40 | -4.10 | −129.3% |
| Nov 15, 2024 | -5.85 | -62.30 | +90.6% |
| Aug 14, 2024 | -139.86 | -0.07 | −199,700.0% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
24No pass
Benjamin Graham
42No pass
Philip Fisher
40No pass
Peter Lynch
56No pass
Joel Greenblatt
0No pass
Charlie Munger
32No pass
Terry Smith
30No pass
Questions about ENDRA Life Sciences
Is ENDRA Life Sciences a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the ENDRA Life Sciences AI analysis
What does ENDRA Life Sciences do?
ENDRA Life Sciences Inc. develops technology for improving the capabilities of clinical diagnostic ultrasound. It is in Medical - Diagnostics & Research.
Does ENDRA Life Sciences pay a dividend?
No. ENDRA Life Sciences does not pay a dividend at the moment.
Is ENDRA Life Sciences stock halal?
Yes. ENDRA Life Sciences passes our halal screen: its business is permitted and its debt is 7% of its market value, under the 30% limit. How we check
How has ENDRA Life Sciences stock done over the past year?
Down 12.5% over the past twelve months, to $4.77. It traded between $3.26 and $6.70 and is 28.8% below its high.
Who are ENDRA Life Sciences's competitors?
The largest listed companies in the same industry are Illumina, Labcorp Holdings, Quest Diagnostics and Guardant Health. The peers table on this page compares their profit, growth and price with ENDRA Life Sciences's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.